Private Industry's Most Eligible - Mining for licensing gold? Look for new prospects outside the US borders. - BioPharm International


Private Industry's Most Eligible
Mining for licensing gold? Look for new prospects outside the US borders.

BioPharm International

In a recent survey of 261 CEOs and licensing executives of biotech companies, 84 percent acknowledged that they face one or more of the following challenges:

Under-the-Radar Gems
  • The ability to identify candidates
  • The competition for attractive compounds
  • Overexposure of US-based licensing opportunities that drive up headline values

Large pharma companies that were historically proud of their protective R&D "not invented here" mentality have developed impressive and effective licensing organizations. So it's no surprise that in 2003, more than 24 percent of sales from the top 20 pharma companies were derived from in-licensed drugs. Following this trend, more and more biotech companies are realizing that they should match licensing competencies to stay competitive and meet investors' requirements for a balanced pipeline.

A majority of executives surveyed (78 percent) said they were "unsatisfied" with the use of commercially available databases. While it may reassure management that all bases are covered, in reality, business development executives who work closely with such systems admit that they spend too much time reviewing out-of-date information and that when an attractive opportunity is finally identified, it tends to be overvalued and too expensive for in-licensing because of its high visibility to all subscribers.

Most companies are mining for gold in the same location—the United States. Because the majority of partnering meetings and financial institution showcases take place in the US, local companies gain higher visibility —and a higher licensing price. Companies that are looking to in-license should move further downstream and dig in a more attractive mine where very few other companies are looking. Exciting technologies are emerging from and are available in less-familiar places such as Israel and Italy, where biotech companies have built solid science but lack the PR resources to share their story. In the next five years, there will be a growing need for licensing collaborations and an increase in headline value of licensing deals. As the supply of attractive licensing opportunities dwindles, more and more companies will be looking both into unexplored biotech regions and into earlier stages of product development.

Ranan Lachman is a principal with 2Value, a New York–based business development firm that identifies licensing opportunities originating from international private biotech companies, start-ups and universities. He can be reached at 212-897-5808 or

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here